In the oncology sector, Mercedon Keytruda's sales in 2020Q3 were $3,715 million, up 21 percent, with $2.2 billion in revenue in the U.S. and about 50 percent of sales from non-lung cancer.
Keytruda's cumulative revenue for the first three quarters of 2020 has reached $10,387 million, up 31 per cent, while Mercer's Lynparza and Lenvima, which are deeply tied to AstraZeneta and Wesfarmers, are also up 58 per cent and 29 per cent respectively in 2020Q3.
vaccine product Gardasil/Gardasil 9 has gradually recovered from the impact of COVID-19, with sales of $1,187 million in 2020Q3, down 10% year-on-year, and cumulative revenue of $2,941 million in the first three quarters of 2020, down 2% year-on-year.
From a regional perspective, Mercedon's 2020Q3 China revenue was $990 million, up 10% YoY, and cumulative revenue for the first three quarters of 2020 reached $2.646 billion, surpassing Japan as Mercer's third largest market outside the U.S. and European Union.
in the development of COVID-19 drugs and vaccines, Mercadon disclosed in its financial results that it had developed an oral antiviral candidate drug, Monupiravir (MK-4482), in partnership with Ridgeback Bio. Two key Phase II/III clinical studies have been initiated, one of which plans to recruit 1,450 outpatient COVID-19 adult patients and the other to recruit 1,300 inpatient COVID-19 adult patients.
candidate vaccine V591 has entered the phase I clinical stage, V590 is about to enter the phase I clinical.
original title: Mercedon First 3rd Quarter 2020 Results: China revenue of $2.646 billion, Keytruda global sales of $10.387 billion